European Commission approves Roche ’s Tecentriq in combination with Abraxane for people with PD-L1-positive, metastatic triple-negative breast cancer

Roche today announced that the European Commission has approved Tecentriq ® (atezolizumab) plus chemotherapy (Abraxane® [paclitaxel protein-bound particles for injectable suspension (albumin-bound); nab-paclitaxel]) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expressio n (≥1%) and who have not received prior chemotherapy for metastatic disease.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news